Further Information
Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
IHC (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
IF: 1-2 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the EGFR antibody to be titered up or down for optimal performance.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
This antibody recognizes a protein of 170kDa, identified as EGFR.?EGFR?is type I receptor tyrosine kinase with sequence homology to?ErbB2, -3 -4 or?HER2, -3 -4. It binds to Epidermal Growth Factor (EGF),?Transforming Growth Factor-a?(TGF-a), Heparin-binding EGF (HB-EGF), amphiregulin, betacellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head/neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
The immunizing protein for this antibody was recombinant human EGFR.
1956
epidermal growth factor receptor
EGF R
Homo sapiens
Liquid
Protein G affinity chromatography
Cancer,Signal Transduction
P00533
Optimal dilutions for each application to be determined by the researcher